PPM1A

Protein phosphatase 1A · P35813 · PPM1A on Sugi Atlas →

801 patent compounds predicted against PPM1A, 505 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15910127	0.36	5/20
Bromide (SCHEMBL6247610)	0.46	4/20
Bromide (SCHEMBL6120521)	0.43	4/20
Bromide (SCHEMBL1866559)	0.42	4/20
Bromide (SCHEMBL4620833)	0.41	4/20
Hydrochloric Acid (SCHEMBL15902009)	0.36	4/20
Hydrochloric Acid (SCHEMBL15902010)	0.36	4/20
SCHEMBL26734061	0.44	3/20
SCHEMBL13646750	0.41	3/20
SCHEMBL29613359	0.41	3/20
Bromide (SCHEMBL11728451)	0.39	3/20
SCHEMBL18029474	0.35	3/20
SCHEMBL17955861	0.34	3/20
SCHEMBL12938345	0.32	3/20
SCHEMBL4315586	0.59	2/20
SCHEMBL4315591	0.59	2/20
SCHEMBL4315593	0.59	2/20
SCHEMBL5497399	0.59	2/20
SCHEMBL13269697	0.59	2/20
SCHEMBL13269698	0.59	2/20

Clinical trials — most relevant to PPM1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Natural History With Focus on Oncological Risk Evaluation in Pediatric Patients With PTEN Pathogenic Variants	nan	RECRUITING
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PPM1A binder may also engage these)

Protein	Name	Similarity
P35814	—	1.000	P35814 →
P20650	—	1.000	P20650 →
P49443	—	1.000	P49443 →
O62829	—	1.000	O62829 →
P35815	—	0.983	P35815 →
P36993	—	0.977	P36993 →
PPM1B	Protein phosphatase 1B	0.975	landscape →
O62830	—	0.972	O62830 →
Q8N3J5	—	0.951	Q8N3J5 →
Q8BXN7	—	0.951	Q8BXN7 →
Q2PC20	—	0.950	Q2PC20 →
Q28DF4	—	0.949	Q28DF4 →
A6K136	—	0.947	A6K136 →
Q9ULR3	—	0.935	Q9ULR3 →
P27119	—	0.933	P27119 →
Q5M821	—	0.933	Q5M821 →
Q91WC3	—	0.931	Q91WC3 →
Q3UYC0	—	0.930	Q3UYC0 →
Q9SD02	—	0.929	Q9SD02 →
P27117	—	0.929	P27117 →
P93006	—	0.927	P93006 →
P27118	—	0.927	P27118 →
ODC1	Ornithine decarboxylase	0.926	landscape →
P27120	—	0.925	P27120 →
Q6ING9	—	0.925	Q6ING9 →
Q9NTI2	—	0.925	Q9NTI2 →
A0A8I5ZNK2	—	0.925	A0A8I5ZNK2 →
Q863I2	—	0.924	Q863I2 →
Q6ZI44	—	0.924	Q6ZI44 →
ACSL6	Long-chain-fatty-acid--CoA ligase 6	0.924	landscape →